Allergic Asthma - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Allergic Asthma - Pipeline Review, H2 2016

Allergic Asthma - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Allergic Asthma - Pipeline Review, H2 2016
Published Aug 10, 2016
181 pages — Published Aug 10, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Allergic Asthma - Pipeline Review, H2 2016, provides an overview of the Allergic Asthma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Allergic Asthma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Allergic Asthma and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Allergic Asthma
- The report reviews pipeline therapeutics for Allergic Asthma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Allergic Asthma therapeutics and enlists all their major and minor projects
- The report assesses Allergic Asthma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Allergic Asthma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Allergic Asthma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Allergic Asthma pipeline depth and focus of Indication therapeutics
-

  
Source:
Document ID
GMDHC8350IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents29
  List of Tables91
  List of Figures101
Introduction111
  Global Markets Direct Report Coverage111
Allergic Asthma Overview121
Therapeutics Development132
  Pipeline Products for Allergic Asthma Overview131
  Pipeline Products for Allergic Asthma Comparative Analysis141
Allergic Asthma Therapeutics under Development by Companies153
Allergic Asthma Therapeutics under Investigation by Universities/Institutes181
Allergic Asthma Pipeline Products Glance193
  Late Stage Products191
  Clinical Stage Products201
  Early Stage Products211
Allergic Asthma Products under Development by Companies223
Allergic Asthma Products under Investigation by Universities/Institutes251
Allergic Asthma Companies Involved in Therapeutics Development2633
  ALK-Abello A/S261
  Allergopharma GmbH &Co. KG271
  Amgen Inc.281
  Aquinox Pharmaceuticals Inc.291
  ASIT biotech s.a.301
  Aslan Pharmaceuticals Pte. Ltd.311
  Chiesi Farmaceutici SpA321
  Circassia Pharmaceuticals Plc331
  CSL Limited341
  F. Hoffmann-La Roche Ltd.351
  Fountain Biopharma Inc.361
  Genentech, Inc.371
  GlaxoSmithKline Plc381
  Hydra Biosciences, Inc.391
  Infinity Pharmaceuticals, Inc.401
  KPI Therapeutics, Inc.411
  Mabtech Limited421
  Marinomed Biotechnologie GmbH431
  Mycenax Biotech Inc.441
  NeoPharm Co., Ltd.451
  Oxagen Limited461
  Panacea Biotec Limited471
  Paradigm Biopharmaceuticals Limited481
  Pharmaxis Limited491
  Protectimmun GmbH501
  Shire Plc511
  Stallergenes Greer plc521
  sterna biologicals Gmbh &Co KG531
  Swecure AB541
  Synermore Biologics Co Ltd551
  The International Biotechnology Center (IBC) Generium561
  Verona Pharma Plc571
  Xencor, Inc.581
Allergic Asthma Therapeutics Assessment5912
  Assessment by Monotherapy Products591
  Assessment by Combination Products601
  Assessment by Target613
  Assessment by Mechanism of Action643
  Assessment by Route of Administration672
  Assessment by Molecule Type692
Drug Profiles7192
  AcTMP-1 Drug Profile711
  Allergen for Allergic Asthma and Allergic Rhinitis Drug Profile721
  AQX-1125 Drug Profile735
  Arabinogalactan Drug Profile781
  ASLAN-004 Drug Profile791
  ASM-8 Drug Profile802
  beta-escin Drug Profile821
  CHF-6001 Drug Profile832
  CSL-311 Drug Profile851
  dalazatide Drug Profile865
  Drug to Inhibit PI3 Kinase Delta for Asthma Drug Profile911
  duvelisib Drug Profile9211
  EP-67 Drug Profile1031
  Epsi-Gam Drug Profile1042
  FB-825 Drug Profile1061
  GNR-044 Drug Profile1071
  GSK-2245035 Drug Profile1082
  hdm-ASIT Drug Profile1101
  HX-100 Drug Profile1112
  Lactococcus lactis G121 Drug Profile1131
  Leukothera Drug Profile1141
  OC-000459 Drug Profile1152
  OC-2417 Drug Profile1171
  omalizumab biosimilar Drug Profile1181
  omalizumab biosimilar Drug Profile1191
  omalizumab biosimilar Drug Profile1201
  omalizumab biosimilar Drug Profile1211
  omalizumab biosimilar Drug Profile1221
  OND-86 Drug Profile1231
  pemirolast potassium Drug Profile1241
  pentosan polysulfate sodium Drug Profile1251
  RG-6149 Drug Profile1261
  RG-7990 Drug Profile1271
  RPL-554 Drug Profile1288
  SB-010 Drug Profile1362
  SG-100 Drug Profile1382
  SM-301 Drug Profile1401
  Small Molecule for Allergic Asthma Drug Profile1411
  Small Molecules for Allergic Asthma Drug Profile1421
  Small Molecules to Inhibit 5-Lipoxygenase for Allergic Asthma Drug Profile1431
  Small Molecules to Inhibit CaMKII for Allergic Asthma Drug Profile1441
  standardized grass pollen [timothy (Phleum pratense)] allergen extract Drug Profile1453
  standardized mite (Dermatophagoides farinae + Dermatophagoides pteronyssinus) allergen extract Drug Profile1482
  standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine Drug Profile1505
  SWE-01 Drug Profile1551
  Synthetic Peptides for Allergic Asthma and Rheumatoid Arthritis Drug Profile1561
  tezepelumab Drug Profile1572
  Vaccine for Allergic Asthma Drug Profile1591
  Vaccine for Grass-Induced Rhinoconjunctivitis and Asthma Drug Profile1602
  XmAb-7195 Drug Profile1621
Allergic Asthma Dormant Projects1634
Allergic Asthma Discontinued Products1671
Allergic Asthma Product Development Milestones16812
  Featured News &Press Releases1681
    Jul 27, 2016: ASLAN Pharmaceuticals Enters Service Agreement with Selexis SA for Development of a Proprietary Cell Line for Expression of ASLAN0041681
    May 16, 2016: Sorrento Announces Positive Data from a Combined Phase 2 &3 Clinical Study of STI-004, an Anti-IgE Biosimilar Antibody1681
    Apr 27, 2016: Journal of the American Medical Association publishes Phase III data from allergic asthma trial with ALK house dust mite SLIT-tablet, ACARIZAX1691
    Jan 14, 2016: ALK announces top-line results from the five-year landmark GRAZAX Asthma Prevention trial in children1701
    Jan 06, 2016: Hydra Biosciences to Present at the 8th Annual Biotech Showcase Conference in San Francisco on Jan. 111711
    Aug 31, 2015: ALK obtains European approval for its house dust mite sublingual allergy immunotherapy tablet against allergic rhinitis and allergic asthma1711
    Jun 26, 2015: Xencor Provides Update on XmAb-7195 And Expansion of Bispecific Oncology Pipeline at R&D Day1721
    May 22, 2015: Successful testing of new drug for allergic asthma1731
    May 18, 2015: Fraunhofer ITEM: Successful Testing of New Drug for Allergic Asthma1741
    Apr 14, 2015: Hydra Biosciences Receives Approval from Health Canada to Begin Phase 1 Trial for HX-1001751
    Jul 11, 2013: Positive results from pivotal Phase III trial of new allergy immunotherapy tablet against house dust mite-induced allergic asthma1761
    Apr 08, 2013: S-Target Achieves In Vivo Proof Of Concept For Its Allergy Vaccine SG1001771
    Mar 27, 2013: Merck Announces FDA Acceptance Of Biologics License Application For Investigational Grass Pollen Allergy Immunotherapy Tablet1781
    Apr 17, 2012: Pharmaxis Completes Phase II Clinical Study With ASM8 In Asthma Patients1782
Appendix1802
  Methodology1801
  Coverage1801
  Secondary Research1801
  Primary Research1801
  Expert Panel Validation1801
  Contact Us1801
  Disclaimer1811

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Allergic Asthma - Pipeline Review, H2 2016" Aug 10, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Allergic-Asthma-Pipeline-Review-H2-2016-2088-16358>
  
APA:
Global Markets Direct - Market Research. (2016). Allergic Asthma - Pipeline Review, H2 2016 Aug 10, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Allergic-Asthma-Pipeline-Review-H2-2016-2088-16358>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.